公开(公告)号：US20230042465A1

公开(公告)日：2023-02-09

申请号：US17860416

申请日：2022-07-08

Applicant: Janssen Biotech, Inc.

Inventor： Ann Donlon ,  Charles Goochee ,  Gary Gordon ,  Ronan Hayes ,  Robin Johnston, JR. ,  Willem Steenvoorden ,  Denis Twomey

IPC: C07K16/24

Abstract: The present invention relates to methods of manufacture for producing anti-TNF antibodies, e.g., the anti-TNF antibody golimumab, and specific pharmaceutical compositions of the antibody.

公开(公告)号：US20220089712A1

公开(公告)日：2022-03-24

申请号：US17489744

申请日：2021-09-29

Applicant: Janssen Biotech, Inc. ,  Janssen Biologics B.V.

Inventor： Marcel Flikweert ,  Charles Goochee ,  Francis C. Maslanka ,  Franciscus Johannes Ignatius Nagel ,  James R. Ryland ,  Eugene Schaefer

IPC: C07K16/24 ,  C07K16/00

Abstract: Provided herein is a method for producing an antibody, such as an anti-TNFα antibody (e.g., infliximab) having a C-terminal lysine content of about 20% to about 70%, and a sialic acid content of about 1% to about 20%, comprising culturing a zinc-responsive host cell transfected with DNA encoding the antibody in a culture medium comprising at least 0.5 μM zinc; and controlling the concentration of zinc in the culture medium, thereby producing the antibody.

公开(公告)号：US20230038355A1

公开(公告)日：2023-02-09

申请号：US17860453

申请日：2022-07-08

Applicant: Janssen Biotech, Inc.

Inventor： Ann Donlon ,  Charles Goochee ,  Ronan Hayes ,  Robin Johnston ,  Willem Steenvoorden ,  Denis Twomey ,  Gary Gordon

IPC: C07K16/24 ,  C12P21/00 ,  C12N5/09

Abstract: The present disclosure relates to methods of manufacture for producing anti-IL-12/IL-23p40 antibodies, e.g., the anti-IL-12/IL-23p40 antibody ustekinumab, and specific pharmaceutical compositions of the antibody.

公开(公告)号：US20140273092A1

公开(公告)日：2014-09-18

申请号：US14207915

申请日：2014-03-13

Applicant: Janssen Biologics B.V. ,  Janssen Biotech, Inc.

Inventor： Marcel Flikweert ,  Charles Goochee ,  Francis Maslanka ,  Franciscus Johannes Ignatius Nagel ,  James Ryland ,  Eugene Schaefer

IPC: C07K16/24

CPC classification number: C07K16/241 ,  C07K16/00 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/40 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/76 ,  C07K2317/92

Abstract: Provided herein is a method for producing an antibody, such as an anti-TNFα antibody (e.g., infliximab) having a C-terminal lysine content of about 20% to about 70%, and a sialic acid content of about 1% to about 20%, comprising culturing a zinc-responsive host cell transfected with DNA encoding the antibody in a culture medium comprising at least 0.5 μM zinc; and controlling the concentration of zinc in the culture medium, thereby producing the antibody.

Abstract translation: 本文提供了一种制备抗体的方法，例如C末端赖氨酸含量为约20％至约70％，唾液酸含量为约1％至约20的抗TNFα抗体（例如，英夫利昔单抗） 包括在包含至少0.5μM锌的培养基中培养用编码抗体的DNA转染的锌应答宿主细胞; 并控制培养基中锌的浓度，从而产生抗体。

公开(公告)号：US11149085B2

公开(公告)日：2021-10-19

申请号：US14757691

申请日：2015-12-23

Applicant: Janssen Biotech, Inc. ,  Janssen Biologies B.V.

Inventor： Marcel Flikweert ,  Charles Goochee ,  Francis C. Maslanka ,  Franciscus Johannes Ignatius Nagel ,  James R. Ryland ,  Eugene Schaefer

IPC: C07K16/24 ,  C07K16/00

Abstract: Provided herein is a method for producing an antibody, such as an anti-TNFα antibody (e.g., infliximab) having a C-terminal lysine content of about 20% to about 70%, and a sialic acid content of about 1% to about 20%, comprising culturing a zinc-responsive host cell transfected with DNA encoding the antibody in a culture medium comprising at least 0.5 μM zinc; and controlling the concentration of zinc in the culture medium, thereby producing the antibody.

公开(公告)号：US20160237149A1

公开(公告)日：2016-08-18

申请号：US14757691

申请日：2015-12-23

Applicant: Janssen Biotech, Inc. ,  Janssen Biologics B.V.

Inventor： Marcel Flikweert ,  Charles Goochee ,  Francis Maslanka ,  Franciscus Johannes Ignatius Nagel ,  James Ryland ,  Eugene Schaefer

IPC: C07K16/24

CPC classification number: C07K16/241 ,  C07K16/00 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/40 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/76 ,  C07K2317/92

Abstract: Provided herein is a method for producing an antibody, such as an anti-TNFα antibody (e.g., infliximab) having a C-terminal lysine content of about 20% to about 70%, and a sialic acid content of about 1% to about 20%, comprising culturing a zinc-responsive host cell transfected with DNA encoding the antibody in a culture medium comprising at least 0.5 μM zinc; and controlling the concentration of zinc in the culture medium, thereby producing the antibody.

Abstract translation: 本文提供了一种制备抗体的方法，例如C末端赖氨酸含量为约20％至约70％，唾液酸含量为约1％至约20的抗TNFα抗体（例如，英夫利昔单抗） 包括在包含至少0.5μM锌的培养基中培养用编码抗体的DNA转染的锌应答宿主细胞; 并控制培养基中锌的浓度，从而产生抗体。